Brief: Lonza Collaborates With Selectimmune Collaborates To Develop Immunotherapeutic Drug Candidate
21/06/2021 14:06
June 21 (Reuters) - LONZA GROUP AG LONN.S :
* SELECTIMMUNE COLLABORATES WITH LONZA TO DEVELOP AN
IMMUNOTHERAPEUTIC DRUG CANDIDATE
* THE AGREEMENT PROVIDES ACCESS TO VECTOR CONSTRUCTION AND
NON-GMP
EXPRESSION OF A NOVEL IMMUNOTHERAPY PROTEIN DRUG CANDIDATE
Further company coverage: LONN.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Selectimmune Pharma AB
See all newsBrief: Selectimmune Pharma Says Co's CEO Ann Gidner Will Leave Selectimmune Pharma
Brief: Lonza Collaborates With Selectimmune Collaborates To Develop Immunotherapeutic Drug Candidate
Brief: Selectimmune Pharma Q2 Pretax Loss Widens To SEK 3.1 Mln
Brief: Selectimmune Pharma Q1 Pretax Loss Narrows To SEK 2.2 Million
Brief: Selectimmune Pharma Signs Deal On Phase II Study For Infection Treatment